|
Patrick Enright is responsible for West Coast venture capital investments in health care, with primary focus on biotechnology, pharmaceuticals, and health care information technology. Mr. Enright has more than 20 years of experience as an investor and as a senior executive. Most recently, he co-managed Delta Opportunity Fund, which specialized in investing in development-stage health-care companies such as SUGEN, Inc. and Cephalon, Inc. Mr. Enright also was a member of PaineWebber Development Corporation, which provided equity capital and product development funding to leading biotechnology firms such as Genentech, Inc., Amgen Inc., Centocor, Inc., and Alkermes, Inc. Mr. Enright's operating experience includes senior roles at Sandoz Corporation, Boehringer Mannheim, and Valentis, Inc. He is on the board of directors of Valentis, Inc., Raven biotechnologies, Inc., NuGEN Technologies, Inc., Threshold Pharmaceuticals, Inc., and Codexis, Inc. Mr. Enright graduated from Stanford University with a BS in Biological Sciences, and he received an MBA from the Wharton School of Business at the University of Pennsylvania. | 